Company Filing History:
4 out of 489 
3 out of 223 
2 out of 238 
Years Active: 2017-2024
Title: Pieter Mestdagh: Innovator in Extracellular Vesicle Research
Introduction
Pieter Mestdagh is a notable inventor based in Bruges, Belgium, recognized for his contributions to the field of extracellular vesicle research. With a total of four patents to his name, he has made significant strides in developing innovative solutions for cancer treatment and diagnostic accuracy.
Latest Patents
Mestdagh's latest patents include groundbreaking work on the usages of recombinant extracellular vesicles. This disclosure focuses on the research and clinical applications of extracellular vesicles, particularly those that incorporate a self-assembling protein and a heterologous marker. These recombinant extracellular vesicles serve as biological reference materials, enhancing the accuracy of extracellular vesicle-based diagnostics and improving the calibration of analysis devices. Another significant patent addresses the inhibition of a long non-coding RNA (lncRNA) for the treatment of neuroblastoma. This research reveals that a specific lncRNA is up-regulated in neuroblastoma cells, and its inhibition leads to reduced cell growth and increased apoptosis, presenting a novel therapeutic strategy for this aggressive cancer.
Career Highlights
Throughout his career, Pieter Mestdagh has worked with esteemed institutions such as Ghent University and VIB (Flanders Institute for Biotechnology). His research has been pivotal in advancing the understanding of extracellular vesicles and their potential applications in medicine.
Collaborations
Mestdagh has collaborated with notable colleagues, including Joke Vandesompele and Jean-Christophe Marine, contributing to the collective knowledge in the field of cancer research and diagnostics.
Conclusion
Pieter Mestdagh's innovative work in extracellular vesicle research and cancer treatment exemplifies the impact of dedicated inventors in advancing medical science. His patents not only enhance diagnostic accuracy but also offer new therapeutic avenues for challenging diseases like neuroblastoma.